Diabetic nephropathy

Diabetology and Metabolic Syndrome

Volumn 1, Issue 1, 2009, Pages

  Zelmanovitz, Themis ^a,b   Gerchman, Fernando ^a   Balthazar, Amely P S ^c   Thomazelli, Fúlvio C S ^d   Matos, Jorge D ^e   Canani, Luís H ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^d REGIONAL UNIVERSITY OF BLUMENAU   (Brazil)

^e FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; METFORMIN; NATEGLINIDE; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ALBUMINURIA; CARDIOVASCULAR MORTALITY; DIABETIC NEPHROPATHY; DIET; DYSLIPIDEMIA; ENZYME GLYCOSYLATION; FOLLOW UP; GENETIC RISK; GLOMERULAR HYPERFILTRATION; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MACROALBUMINURIA; META ANALYSIS (TOPIC); MICROALBUMINURIA; MULTICENTER STUDY (TOPIC); PATHOLOGY; PATHOPHYSIOLOGY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SCREENING; SMOKING; ULTRAFILTRATION;

EID: 77953436076     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-1-10     Document Type: Review

References (181)

1. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003.
2. Prognostic factors in Brazilian diabetic patients starting dialysis: a 3.6-year follow-up study. Bruno RM, Gross JL, J Diabetes Complications 2000 14 266 271 10.1016/S1056-8727(00)00118-5 11113689
3. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Valmadrid CT, Klein R, Moss SE, Klein BE, Arch Intern Med 2000 160 1093 1100 10.1001/archinte.160.8.1093 10789601
4. Predicting diabetic nephropathy in insulin-dependent patients. Mogensen CE, Christensen CK, N Engl J Med 1984 311 89 93 6738599
5. Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Parving HH, Oxenboll B, Svendsen PA, Christiansen JS, Andersen AR, Acta Endocrinol (Copenh) 1982 100 550 555 6812342
6. Microalbuminuria as a predictor of clinical nephropathy in insulin- dependent diabetes mellitus. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H, Lancet 1982 1 1430 1432 10.1016/S0140-6736(82)92450-3 6123720
7. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. Mogensen CE, N Engl J Med 1984 310 356 360 6690964
8. Nonalbuminuric renal insufficiency in type 2 diabetes. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G, Diabetes Care 2004 27 195 200 10.2337/diacare.27.1.195 14693989
9. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Caramori ML, Fioretto P, Mauer M, Diabetes 2003 52 1036 1040 10.2337/diabetes.52.4.1036 12663477
10. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Kramer CK, Leitao CB, Pinto LC, Silveiro SP, Gross JL, Canani LH, Diabetes Care 2007 30 1998 2000 10.2337/dc07-0387 17468344
11. Early nephropathy in type 1 diabetes: the importance of early renal function decline. Perkins BA, Krolewski AS, Curr Opin Nephrol Hypertens 2009 18 233 240 10.1097/MNH.0b013e3283293db1 19300247
12. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Young BA, Maynard C, Boyko EJ, Diabetes Care 2003 26 2392 2399 10.2337/diacare.26.8.2392 12882868
13. Vascular complications of black patients with type 2 diabetes mellitus in Southern Brazil. Gerchman F, Zanatta CM, Burttet LM, Picon PX, Lisboa HR, Silveiro SP, Gross JL, Canani LH, Braz J Med Biol Res 2008 41 668 673 18797699
14. Nephropathy in Diabetes. American Diabetes Association, Diabetes Care 2004 27 79 83 10.2337/diacare.27.2007.S79 14693934
15. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Caramori ML, Fioretto P, Mauer M, Diabetes 2000 49 1399 1408 10.2337/diabetes.49.9.1399 10969821
16. Regression of microalbuminuria in type 1 diabetes. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS, N Engl J Med 2003 348 2285 2293 10.1056/NEJMoa021835 12788992
17. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Dinneen SF, Gerstein HC, Arch Intern Med 1997 157 1413 1418 10.1001/archinte.157.13.1413 9224218
18. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH, Diabetes 2002 51 1157 1165 10.2337/diabetes.51.4.1157 11916939
19. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Forsblom CM, Groop PH, Ekstrand A, Totterman KJ, Sane T, Saloranta C, Groop L, Diabetes Care 1998 21 1932 1938 10.2337/diacare.21.11.1932 9802746
20. Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study. Murussi M, Baglio P, Gross JL, Silveiro SP, Diabetes Care 2002 25 1101 1103 10.2337/diacare.25.6.1101 12032128
21. Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. The Microalbuminuria Collaborative Study Group. Diabet Med 1999 16 918 925 10.1046/j.1464-5491.1999.00182.x 10588521
22. Urinary albumin excretion rate is associated with increased ambulatory blood pressure in normoalbuminuric type 2 diabetic patients. Leitao CB, Canani LH, Polson PB, Molon MP, Pinotti AF, Gross JL, Diabetes Care 2005 28 1724 1729 10.2337/diacare.28.7.1724 15983326
23. Monitoring glomerular function in diabetic nephropathy. A prospective study. Viberti GC, Bilous RW, Mackintosh D, Keen H, Am J Med 1983 74 256 264 10.1016/0002-9343(83)90624-1 6401924
24. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Gall MA, Nielsen FS, Smidt UM, Parving HH, Diabetologia 1993 36 1071 1078 10.1007/BF02374501 8243857
25. Evolution of glomerular filtration rate in proteinuric NIDDM patients. Friedman R, Gross JL, Diabetes Care 1991 14 355 359 10.2337/diacare.14.5.355 2060446
26. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Nosadini R, Velussi M, Brocco E, Bruseghin M, Abaterusso C, Saller A, Dalla Vestra M, Carraro A, Bortoloso E, Sambataro M, Barzon I, Frigato F, Muollo B, Chiesura-Corona M, Pacini G, Baggio B, Piarulli F, Sfriso A, Fioretto P, Diabetes 2000 49 476 484 10.2337/diabetes.49.3.476 10868971
27. Standards of medical care in diabetes - 2009. Diabetes Care 2009 32 Suppl 1 13 61 19118286
28. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ, Diabetes Care 1997 20 516 519 10.2337/diacare.20.4.516 9096972
29. Evaluation of tests for microalbuminuria screening in patients with diabetes. Incerti J, Zelmanovitz T, Camargo JL, Gross JL, de Azevedo MJ, Nephrol Dial Transplant 2005 20 2402 2407 10.1093/ndt/gfi074 16105865
30. Diabetic nephropathy: diagnosis, prevention, and treatment. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T, Diabetes Care 2005 28 164 176 10.2337/diacare.28.1.164 15616252
31. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, Froland A, Hansen KW, Nielsen S, Pedersen MM, Diabetes Care 1995 18 572 581 7497874
32. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G, Kidney Int 2005 67 2089 2100 10.1111/j.1523-1755.2005.00365.x 15882252
33. Proteinuria: pathophysiology, significance and recommendations for measurement in clinical practice. Beetham R, Cattell WR, Ann Clin Biochem 1993 30 Pt 5 425 434 8250494
34. Does bacteriuria interfere with albuminuria measurements of patients with diabetes? Kramer CK, Camargo J, Ricardo ED, Almeida FK, Canani LH, Gross JL, Azevedo MJ, Nephrol Dial Transplant 2009 24 1193 1196 10.1093/ndt/gfn629 19015170
35. High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Comper WD, Osicka TM, Jerums G, Am J Kidney Dis 2003 41 336 342 10.1053/ajkd.2003.50041 12552494
36. Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. Brinkman JW, Bakker SJ, Gansevoort RT, Hillege HL, Kema IP, Gans RO, de Jong PE, de Zeeuw D, Kidney Int Suppl 2004 69 75 10.1111/j.1523-1755.2004.09219.x 15485424
37. Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay. Comper WD, Osicka TM, Clark M, MacIsaac RJ, Jerums G, Kidney Int 2004 65 1850 1855 10.1111/j.1523-1755.2004.00585.x 15086926
38. Detection of urinary albumin. Comper WD, Osicka TM, Adv Chronic Kidney Dis 2005 12 170 176 10.1053/j.ackd.2005.01.012 15822052
39. New and old markers of progression of diabetic nephropathy. Jerums G, Premaratne E, Panagiotopoulos S, Clarke S, Power DA, MacIsaac RJ, Diabetes Res Clin Pract 2008 82 Suppl 1 30 37 10.1016/j.diabres.2008.09.032 18937992
40. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G, Ann Intern Med 2003 139 137 147 12859163
41. Reference values for 51Cr-EDTA clearance as a measure of glomerular filtration rate. Granerus G, Aurell M, Scand J Clin Lab Invest 1981 41 611 616 10.3109/00365518109090505 6801756
42. Renal function and structure in albuminuric type 2 diabetic patients without retinopathy. Christensen PK, Larsen S, Horn T, Olsen S, Parving HH, Nephrol Dial Transplant 2001 16 2337 2347 10.1093/ndt/16.12.2337 11733625
43. Diabetic Nephropathy. Mauer M, Fioretto P, Woredekal Y, Friedman EA, Diseases of the Kidney and Urinary Tract Lippincott Williams & Wilkins, Schrier RW, 7 2001 2083 2116
44. Renal pathological change in patients with type 2 diabetes is not always diabetic nephropathy: a report of 52 cases. Huang F, Yang Q, Chen L, Tang S, Liu W, Yu X, Clin Nephrol 2007 67 293 297 17542338
45. Renal outcome in type 2 diabetic patients with or without coexisting nondiabetic nephropathies. Wong TY, Choi PC, Szeto CC, To KF, Tang NL, Chan AW, Li PK, Lai FM, Diabetes Care 2002 25 900 905 10.2337/diacare.25.5.900 11978688
46. The changing natural history of nephropathy in type I diabetes. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR, Am J Med 1985 78 785 794 10.1016/0002-9343(85)90284-0 3993659
47. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Krolewski AS, Kidney Int 1999 55 1582 1596 10.1046/j.1523-1755.1999.00371.x 10201028
48. Genetics of diabetic nephropathy: how far are we from finding susceptibility genes? Krolewski AS, Ng DP, Canani LH, Warram JH, Adv Nephrol Necker Hosp 2001 31 295 315 11692468
49. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Quinn M, Angelico MC, Warram JH, Krolewski AS, Diabetologia 1996 39 940 945 10.1007/BF00403913 8858216
50. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC, Diabetologia 1990 33 438 443 10.1007/BF00404096 2401399
51. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Freedman BI, Tuttle AB, Spray BJ, Am J Kidney Dis 1995 25 710 713 10.1016/0272-6386(95)90546-4 7747724
52. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997 46 1829 1839 10.2337/diabetes.46.11.1829 9356033
53. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Canani LH, Gerchman F, Gross JL, Diabetes 1999 48 909 913 10.2337/diabetes.48.4.909 10102711
54. Evidence for different susceptibility genes for proteinuria and ESRD in type 2 diabetes. Placha G, Canani LH, Warram JH, Krolewski AS, Adv Chronic Kidney Dis 2005 12 155 169 10.1053/j.ackd.2005.02.002 15822051
55. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH, BMJ 1997 314 783 788 9080995
56. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R, Arch Intern Med 1998 158 998 1004 10.1001/archinte.158.9.998 9588433
57. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, BMJ 2000 321 405 412 10.1136/bmj.321.7258.405 10938048
58. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Alaveras AE, Thomas SM, Sagriotis A, Viberti GC, Nephrol Dial Transplant 1997 12 Suppl 2 71 74 9269705
59. Smoking and progression of diabetic nephropathy in type 1 diabetes. Hovind P, Rossing P, Tarnow L, Parving HH, Diabetes Care 2003 26 911 916 10.2337/diacare.26.3.911 12610058
60. Reversal of lesions of diabetic nephropathy after pancreas transplantation. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M, N Engl J Med 1998 339 69 75 10.1056/NEJM199807093390202 9654536
61. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, N Engl J Med 2008 358 2560 2572 10.1056/NEJMicm066227 18539916
62. Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes. Park JY, Kim HK, Chung YE, Kim SW, Hong SK, Lee KU, Diabetes Care 1998 21 530 534 10.2337/diacare.21.4.530 9571337
63. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR, BMJ 2000 321 412 419 10.1136/bmj.321.7258.412 10938049
64. Smoking is associated with progression of diabetic nephropathy. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M, Diabetes Care 1994 17 126 131 10.2337/diacare.17.2.126 8137682
65. Determinants of progression of microalbuminuria in patients with NIDDM. A prospective study. Smulders YM, Rakic M, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J, Diabetes Care 1997 20 999 1005 10.2337/diacare.20.6.999 9167114
66. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. Chaturvedi N, Fuller JH, Taskinen MR, Diabetes Care 2001 24 2071 2077 10.2337/diacare.24.12.2071 11723085
67. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL, Kidney Int 2003 64 817 828 10.1046/j.1523-1755.2003.00164.x 12911531
68. Cholesterol: a renal risk factor in diabetic nephropathy? Mulec H, Johnsen SA, Wiklund O, Bjorck S, Am J Kidney Dis 1993 22 196 201 8322783
69. Nephropathy of type-2 diabetes mellitus. Ruggenenti P, Remuzzi G, J Am Soc Nephrol 1998 9 2157 2169 9808106
70. Understanding the nature of renal disease progression. Remuzzi G, Ruggenenti P, Benigni A, Kidney Int 1997 51 2 15 10.1038/ki.1997.2 8995712
71. Glomerular filtration rate, urinary albumin excretion rate, and blood pressure changes in normoalbuminuric normotensive type 1 diabetic patients: an 8-year follow-up study. Caramori ML, Gross JL, Pecis M, de Azevedo MJ, Diabetes Care 1999 22 1512 1516 10.2337/diacare.22.9.1512 10480518
72. Glomerular hyperfiltration in NIDDM patients without overt proteinuria. Silveiro SP, Friedman R, Gross JL, Diabetes Care 1993 16 115 119 10.2337/diacare.16.1.115 8422764
73. The hyperfiltration theory: a paradigm shift in nephrology. Brenner BM, Lawler EV, Mackenzie HS, Kidney Int 1996 49 1774 1777 10.1038/ki.1996.265 8743495
74. Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients. Dahlquist G, Stattin EL, Rudberg S, Nephrol Dial Transplant 2001 16 1382 1386 10.1093/ndt/16.7.1382 11427629
75. Urinary albumin excretion rate and glomerular filtration rate in single-kidney type 2 diabetic patients. Silveiro SP, da Costa LA, Beck MO, Gross JL, Diabetes Care 1998 21 1521 1524 10.2337/diacare.21.9.1521 9727902
76. Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes. Ficociello LH, Perkins BA, Roshan B, Weinberg JM, Aschengrau A, Warram JH, Krolewski AS, Diabetes Care 2009 32 889 893 10.2337/dc08-1560 19196883
77. Having one kidney does not accelerate the rate of development of diabetic nephropathy lesions in type 1 diabetic patients. Chang S, Caramori ML, Moriya R, Mauer M, Diabetes 2008 57 1707 1711 10.2337/db07-1610 18375439
78. Glomerular hyperfiltration in the prediction of nephropathy in IDDM: a 10-year follow-up study. Yip JW, Jones SL, Wiseman MJ, Hill C, Viberti G, Diabetes 1996 45 1729 1733 10.2337/diabetes.45.12.1729 8922358
79. Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Toeller M, Buyken A, Heitkamp G, Bramswig S, Mann J, Milne R, Gries FA, Keen H, Diabetologia 1997 40 1219 1226 10.1007/s001250050810 9349605
80. Higher intakes of fish protein are related to a lower risk of microalbuminuria in young Swedish type 1 diabetic patients. Mollsten AV, Dahlquist GG, Stattin EL, Rudberg S, Diabetes Care 2001 24 805 810 10.2337/diacare.24.5.805 11347734
81. Chicken and fish diet reduces glomerular hyperfiltration in IDDM patients. Pecis M, de Azevedo MJ, Gross JL, Diabetes Care 1994 17 665 672 10.2337/diacare.17.7.665 7924775
82. Microalbuminuria is positively associated with usual dietary saturated fat intake and negatively associated with usual dietary protein intake in people with insulin-dependent diabetes mellitus. Riley MD, Dwyer T, Am J Clin Nutr 1998 67 50 57 9440375
83. Sources of protein and polyunsaturated fatty acids of the diet and microalbuminuria in type 2 diabetes mellitus. Almeida JC, Zelmanovitz T, Vaz JS, Steemburgo T, Perassolo MS, Gross JL, Azevedo MJ, J Am Coll Nutr 2008 27 528 537 18845702
84. Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, population-based, observational multicenter study. Cardenas C, Bordiu E, Bagazgoitia J, Calle-Pascual AL, Diabetes Care 2004 27 1454 1457 10.2337/diacare.27.6.1454 15161805
85. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. Seaquist ER, Goetz FC, Rich S, Barbosa J, N Engl J Med 1989 320 1161 1165 2710189
86. A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. Krolewski AS, Poznik GD, Placha G, Canani L, Dunn J, Walker W, Smiles A, Krolewski B, Fogarty DG, Moczulski D, Araki S, Makita Y, Ng DP, Rogus J, Duggirala R, Rich SS, Warram JH, Kidney Int 2006 69 129 136 10.1038/sj.ki.5000023 16374433
87. Genome-wide Association Scan for Diabetic Nephropathy Susceptibility Genes in Type 1 Diabetes Mellitus. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DP, Placha G, Canani LH, Bochenski J, Waggott D, Merchant ML, Krolewski B, Mirea L, Wanic K, Katavetin P, Kure M, Wolkow P, Dunn JS, Smiles A, Walker WH, Boright AP, Bull SB, Doria A, Rogus JJ, Rich SS, Warram JH, Krolewski AS, Diabetes 2009
88. High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach. Rogus JJ, Poznik GD, Pezzolesi MG, Smiles AM, Dunn J, Walker W, Wanic K, Moczulski D, Canani L, Araki S, Makita Y, Warram JH, Krolewski AS, Diabetes 2008 57 2519 2526 10.2337/db07-1086 18559660
89. Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: a randomized crossover trial. Gross JL, Zelmanovitz T, Moulin CC, De Mello V, Perassolo M, Leitao C, Hoefel A, Paggi A, Azevedo MJ, Diabetes Care 2002 25 645 651 10.2337/diacare.25.4.645 11919119
90. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Boright AP, Paterson AD, Mirea L, Bull SB, Mowjoodi A, Scherer SW, Zinman B, Diabetes 2005 54 1238 1244 10.2337/diabetes.54.4.1238 15793268
91. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Brosius FC 3rd, Rev Endocr Metab Disord 2008 9 245 254 10.1007/s11154-008-9100-6 18726161
92. Risk Factors for Micro and Macrovascular Disease in black and white Patients with Type 2 Diabetes Mellitus. Kramer CK, Leitao CB, Pinto LC, Bolson P, Boza J, Silveiro SP, Gross JL, Canani LH, Revista Associação Médica Brasileira 2009
93. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture. Fioretto P, Caramori ML, Mauer M, Diabetologia 2007 51 1347 1355 10.1007/s00125-008-1051-7
94. The pathogenesis of diabetic nephropathy. Dronavalli S, Duka I, Bakris GL, Nat Clin Pract Endocrinol Metab 2008 4 444 452 10.1038/ncpendmet0894 18607402
95. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Wolf G, Chen S, Ziyadeh FN, Diabetes 2005 54 1626 1634 10.2337/diabetes.54.6.1626 15919782
96. Functional and structural changes in the kidney in the early stages of obesity. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE, J Am Soc Nephrol 2001 12 1211 1217 11373344
97. The effects of weight loss on renal function in patients with severe obesity. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y, J Am Soc Nephrol 2003 14 1480 1486 10.1097/01.ASN.0000068462.38661.89 12761248
98. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Zanatta CM, Gerchman F, Burttet L, Nabinger G, Jacques-Silva MC, Canani LH, Gross JL, Diabetes Res Clin Pract 2008 80 299 304 10.1016/j.diabres.2007.12.024 18346810
99. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, Ziyadeh FN, Lewis EJ, Am J Kidney Dis 1999 34 818 823 10.1016/S0272-6386(99)70037-5 10561136
100. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. Hogan M, Cerami A, Bucala R, J Clin Invest 1992 90 1110 1115 10.1172/JCI115928 1522220
101. Advanced glycosylation end products in patients with diabetic nephropathy. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H, N Engl J Med 1991 325 836 842 1875967
102. Pathogenesis, prevention, and treatment of diabetic nephropathy. Cooper ME, Lancet 1998 352 213 219 10.1016/S0140-6736(98)01346-4 9683226
103. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Yamagishi S, Fukami K, Ueda S, Okuda S, Curr Drug Targets 2007 8 952 959 10.2174/138945007781386884 17691932
104. Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes. Yamagishi S, Matsui T, Ueda S, Nakamura K, Imaizumi T, Cardiovasc Hematol Agents Med Chem 2007 5 236 240 10.2174/187152507781058681 17630950
105. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ, Lancet 2005 366 2026 2033 10.1016/S0140-6736(05)67814-2 16338452
106. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis. Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN, Am J Hypertens 2008 21 922 929 10.1038/ajh.2008.206 18535536
107. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 329 977 986 10.1056/NEJM199309303291401 8366922
108. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003 290 2159 2167 10.1001/jama.290.16.2159 14570951
109. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 837 853 10.1016/S0140-6736(98)07019-6 9742976
110. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Shichiri M, Kishikawa H, Ohkubo Y, Wake N, Diabetes Care 2000 23 Suppl 2 21 29 10860187
111. 10-year follow-up of intensive glucose control in type 2 diabetes. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA, N Engl J Med 2008 359 1577 1589 10.1056/NEJMoa0806470 18784090
112. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995 47 1703 1720 10.1038/ki.1995.236 7643540
113. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Microalbuminuria Collaborative Study Group, United Kingdom. BMJ 1995 311 973 977 7580637
114. Glucose control and vascular complications in veterans with type 2 diabetes. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, N Engl J Med 2009 360 129 139 10.1056/NEJMoa0808431 19092145
115. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 317 703 713 9732337
116. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, JAMA 2003 289 2560 2572 10.1001/jama.289.19.2560 12748199
117. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, Lancet 1998 351 1755 1762 10.1016/S0140-6736(98)04311-6 9635947
118. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. Mogensen CE, J Intern Med 2003 254 45 66 10.1046/j.1365-2796.2003.01157.x 12823642
119. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J, Am J Kidney Dis 2000 36 646 661 10977801
120. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Vijan S, Hayward RA, Ann Intern Med 2003 138 593 602 12667032
121. A practical approach to achieving recommended blood pressure goals in diabetic patients. Bakris GL, Arch Intern Med 2001 161 2661 2667 10.1001/archinte.161.22.2661 11732930
122. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, Raffaele J, Tsalamandris C, Am J Kidney Dis 2001 37 890 899 10.1016/S0272-6386(05)80003-4 11325669
123. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, Lancet 2002 359 1004 1010 10.1016/S0140-6736(02)08090-X 11937179
124. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R, Ann Intern Med 1998 128 982 988 9625684
125. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000 355 253 259 10.1016/S0140-6736(99)12323-7 10675071
126. Renal and retinal effects of enalapril and losartan in type 1 diabetes. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R, N Engl J Med 2009 361 40 51 10.1056/NEJMoa0808400 19571282
127. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Viberti G, Wheeldon NM, Circulation 2002 106 672 678 10.1161/01.CIR.0000024416.33113.0A 12163426
128. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001 134 370 379 11242497
129. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, N Engl J Med 2001 345 870 878 10.1056/NEJMoa011489 11565519
130. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Parving HH, Andersen AR, Smidt UM, Svendsen PA, Lancet 1983 1 1175 1179 10.1016/S0140-6736(83)92462-5 6133986
131. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Rossing P, Hommel E, Smidt UM, Parving HH, Diabetologia 1994 37 511 516 10.1007/s001250050140 8056190
132. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL, Ann Intern Med 1995 123 754 762 7574193
133. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, N Engl J Med 1993 329 1456 1462 10.1056/NEJM199311113292004 8413456
134. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, N Engl J Med 2001 345 861 869 10.1056/NEJMoa011161 11565518
135. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, N Engl J Med 2001 345 851 860 10.1056/NEJMoa011303 11565517
136. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Andersen S, Jacobsen P, Tarnow L, Rossing P, Juhl TR, Parving HH, Nephrol Dial Transplant 2003 18 293 297 10.1093/ndt/18.2.293 12543883
137. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Weinberg MS, Kaperonis N, Bakris GL, Curr Hypertens Rep 2003 5 418 425 10.1007/s11906-003-0088-8 12948435
138. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Bakris GL, Weir MR, Arch Intern Med 2000 160 685 693 10.1001/archinte.160.5.685 10724055
139. The impact of atherosclerotic renovascular disease on diabetic renal failure. Nicholls AJ, Diabet Med 2002 19 889 894 10.1046/j.1464-5491.2002.00813.x 12421424
140. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME, BMJ 2000 321 1440 1444 10.1136/bmj.321.7274.1440 11110735
141. Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus. Rosner MH, Okusa MD, Arch Intern Med 2003 163 1025 1029 10.1001/archinte.163.9.1025 12742799
142. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, Lancet 2008 372 547 553 10.1016/S0140-6736(08)61236-2 18707986
143. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P, Clin J Am Soc Nephrol 2009 4 361 368 10.2215/CJN.03350708 19118120
144. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Yoneda T, Takeda Y, Usukura M, Oda N, Takata H, Yamamoto Y, Karashima S, Yamagishi M, Am J Hypertens 2007 20 1329 1333 10.1016/j.amjhyper.2007.09.001 18047925
145. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Sato A, Hayashi K, Naruse M, Saruta T, Hypertension 2003 41 64 68 10.1161/01.HYP.0000044937.95080.E9 12511531
146. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF, Clin J Am Soc Nephrol 2009 4 542 551 10.2215/CJN.04750908 19261819
147. Aliskiren combined with losartan in type 2 diabetes and nephropathy. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, N Engl J Med 2008 358 2433 2446 10.1056/NEJMoa0708379 18525041
148. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA, Nephrol Dial Transplant 2009 24 1663 1671 10.1093/ndt/gfn721 19145003
149. Metformin. Bailey CJ, Turner RC, N Engl J Med 1996 334 574 579 10.1056/NEJM199602293340906 8569826
150. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M, Eur J Intern Med 2002 13 428 10.1016/S0953-6205(02)00131-0 12384131
151. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Shaw JS, Wilmot RL, Kilpatrick ES, Diabet Med 2007 24 1160 1163 10.1111/j.1464-5491.2007.02221.x 17672860
152. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. Inzucchi SE, JAMA 2002 287 360 372 10.1001/jama.287.3.360 11790216
153. Management of drugs affecting blood glucose in diabetic patients with renal failure. Charpentier G, Riveline JP, Varroud-Vial M, Diabetes Metab 2000 26 Suppl 4 73 85 10922977
154. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Harrower AD, Clin Pharmacokinet 1996 31 111 119 10.2165/00003088-199631020-00003 8853933
155. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Hasslacher C, Diabetes Care 2003 26 886 891 10.2337/diacare.26.3.886 12610054
156. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP, Diabetes Care 2003 26 2075 2080 10.2337/diacare.26.7.2075 12832316
157. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, Hasslacher C, Eur J Clin Pharmacol 2001 57 147 152 10.1007/s002280100280 11417447
158. Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Nagai T, Imamura M, Iizuka K, Mori M, Diabetes Res Clin Pract 2003 59 191 194 10.1016/S0168-8227(02)00242-5 12590015
159. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Inoue T, Shibahara N, Miyagawa K, Itahana R, Izumi M, Nakanishi T, Takamitsu Y, Clin Nephrol 2003 60 90 95 12940610
160. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus. Reuser AJ, Wisselaar HA, Eur J Clin Invest 1994 24 Suppl 3 19 24 8001622
161. Antiproteinuric and anti-inflammatory effects of thiazolidinedione. Szeto CC, Li PK, Nephrology (Carlton) 2008 13 53 57 18199104
162. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Iglesias P, Diez JJ, Eur J Endocrinol 2006 154 613 621 10.1530/eje.1.02134 16645006
163. Rosiglitazone reduces urinary albumin excretion in type II diabetes. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI, J Hum Hypertens 2003 17 7 12 10.1038/sj.jhh.1001444 12571611
164. Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Kincaid-Smith P, Fairley KF, Farish S, Best JD, Proietto J, Nephrology (Carlton) 2008 13 58 62 18199105
165. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Pistrosch F, Herbrig K, Kindel B, Passauer J, Fischer S, Gross P, Diabetes 2005 54 2206 2211 10.2337/diabetes.54.7.2206 15983223
166. Thiazolidinedione use and bone loss in older diabetic adults. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR, J Clin Endocrinol Metab 2006 91 3349 3354 10.1210/jc.2005-2226 16608888
167. Use of thiazolidinediones and fracture risk. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR, Arch Intern Med 2008 168 820 825 10.1001/archinte.168.8.820 18443256
168. Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone? Scherbaum WA, Nat Clin Pract Nephrol 2006 2 312 313 10.1038/ncpneph0199 16932451
169. Meta-analysis of small trials: proceed with caution. Farkouh ME, Fuster V, Nat Clin Pract Nephrol 2008 4 115 10.1038/ncpcardio1064 18326067
170. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Loke YK, Singh S, Furberg CD, CMAJ 2009 180 32 39 19073651
171. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA, Diabetes Care 2007 30 1862 1864 10.2337/dc06-2545 17468348
172. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D, Diabetes Obes Metab 2008 10 545 555 10.1111/j.1463-1326.2008.00914.x 18518892
173. Effect of renal impairment on the pharmacokinetics of exenatide. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R, Br J Clin Pharmacol 2007 64 317 327 10.1111/j.1365-2125.2007.02890.x 17425627
174. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH, Ann Intern Med 1996 124 627 632 8607590
175. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH, Kidney Int 2002 62 220 228 10.1046/j.1523-1755.2002.00421.x 12081581
176. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Pijls LT, de Vries H, van Eijk JT, Donker AJ, Eur J Clin Nutr 2002 56 1200 1207 10.1038/sj.ejcn.1601474 12494305
177. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Pan Y, Guo LL, Jin HM, Am J Clin Nutr 2008 88 660 666 18779281
178. Withdrawal of red meat from the usual diet reduces albuminuria and improves serum fatty acid profile in type 2 diabetes patients with macroalbuminuria. de Mello VD, Zelmanovitz T, Perassolo MS, Azevedo MJ, Gross JL, Am J Clin Nutr 2006 83 1032 1038 16685043
179. Long-term effect of a chicken-based diet versus enalapril on albuminuria in type 2 diabetic patients with microalbuminuria. de Mello VD, Zelmanovitz T, Azevedo MJ, de Paula TP, Gross JL, J Ren Nutr 2008 18 440 447 10.1053/j.jrn.2008.04.010 18721739
180. Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS). Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, Demicco DA, Fuller JH, Am J Kidney Dis 2009
181. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O, N Engl J Med 2003 348 383 393 10.1056/NEJMoa021778 12556541